Lamivudine Teva Pharma B.V.

Lamivudine, the active ingredient in Lamivudine Teva Pharma B.V., is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral tablet for oral use. It is used to treat HIV infection and chronic hepatitis B in adults and children as prescribed by a healthcare professional.

GNH USA supplies Lamivudine Teva Pharma B.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is an antiretroviral nucleoside analogue that targets viral replication in specific infections. - HIV infection: reduces plasma HIV‑1 RNA levels and helps restore immune function. - Chronic hepatitis B: suppresses HBV DNA replication, decreasing liver inflammation and disease progression. - HIV/HBV co‑infection: controls both viruses simultaneously, improving overall clinical outcomes.

Lamivudine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: reduced energy levels. - Diarrhea: loose stools. - Insomnia: difficulty sleeping. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance requiring immediate care. - Hepatotoxicity: significant liver enzyme elevation or failure. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: rash, fever, eosinophilia. - Anemia: marked reduction in red blood cells.

Before initiating lamivudine therapy, consider the following safety measures. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic disease: monitor liver enzymes regularly. - Pregnancy: risk category unknown; discuss potential benefits and risks with a physician. - Lactation: unknown excretion in breast milk; weigh maternal benefit against infant risk. - Drug resistance: perform virologic monitoring to detect resistance development. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Lamivudine may interact with other medicines; review the following categories.

Major Interactions (Avoid): - Didanosine: concurrent use increases risk of pancreatitis. - Stavudine: combined therapy may heighten mitochondrial toxicity.

Moderate Interactions (Monitor Closely): - Tenofovir: additive renal toxicity; monitor kidney function. - Nevirapine: hepatic enzyme induction may alter lamivudine levels. - Efavirenz: overlapping central nervous system effects; observe for increased neuropsychiatric symptoms.